Table 4.
Proportion of participants who strongly agreed to each genome sequencing knowledge item before and after consent process (N=311).
| Knowledge concept | Pre-consenta | Post-consent | p-value | ||
|---|---|---|---|---|---|
| N | (%) | N | (%) | ||
| Sequencing limitations | |||||
| Once a risk-increasing variant is found, the disease cannot always be prevented or cured | 163 | (53.8%) | 191 | (67.0%) | <.0001 |
| Genome sequencing cannot tell someone their exact disease risk | 158 | (52.1%) | 184 | (64.1%) | <.0001 |
| Effects of all variants on disease risk are not known | 166 | (54.6%) | 187 | (65.2%) | <.0001 |
| People with a risk-increasing variant may not develop the disease | 166 | (54.6%) | 186 | (65.0%) | 0.001 |
| Genome sequencing is not a routine test available from physicians | 200 | (65.8%) | 206 | (71.8%) | 0.03 |
| Sequencing benefits | |||||
| Genome sequencing may find variants that people can pass on to their children | 253 | (83.2%) | 247 | (85.8%) | 0.21 |
| People can learn about risk for several diseases through genome sequencing. | 191 | (62.8%) | 220 | (76.9%) | <.0001 |
| Genome sequencing may find risk-increasing variants | 220 | (72.1%) | 231 | (80.2%) | 0.006 |
| Genome sequencing may find risk-decreasing variants | 66 | (22.0%) | 78 | (27.6%) | 0.02 |
| Genome sequencing may find variants that affect drug response | 86 | (28.5%) | 106 | (37.1%) | <.0001 |
| Health habits also affect disease risk | 79 | (26.2%) | 85 | (30.0%) | 0.03 |
a
Correct answers were defined as “strongly agree” for each item as shown in Appendix A.